IL247529B - Preparations of choline ester lipoic acid and methods of use - Google Patents

Preparations of choline ester lipoic acid and methods of use

Info

Publication number
IL247529B
IL247529B IL247529A IL24752916A IL247529B IL 247529 B IL247529 B IL 247529B IL 247529 A IL247529 A IL 247529A IL 24752916 A IL24752916 A IL 24752916A IL 247529 B IL247529 B IL 247529B
Authority
IL
Israel
Prior art keywords
methods
lipoic acid
choline ester
ester compositions
acid choline
Prior art date
Application number
IL247529A
Other languages
English (en)
Hebrew (he)
Other versions
IL247529A0 (en
Original Assignee
Encore Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encore Vision Inc filed Critical Encore Vision Inc
Publication of IL247529A0 publication Critical patent/IL247529A0/en
Publication of IL247529B publication Critical patent/IL247529B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL247529A 2014-03-03 2016-08-29 Preparations of choline ester lipoic acid and methods of use IL247529B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461947378P 2014-03-03 2014-03-03
PCT/US2015/018505 WO2015134510A1 (en) 2014-03-03 2015-03-03 Lipoic acid choline ester compositions and methods of use

Publications (2)

Publication Number Publication Date
IL247529A0 IL247529A0 (en) 2016-11-30
IL247529B true IL247529B (en) 2020-10-29

Family

ID=54055796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247529A IL247529B (en) 2014-03-03 2016-08-29 Preparations of choline ester lipoic acid and methods of use

Country Status (12)

Country Link
US (2) US20160354340A1 (enExample)
EP (1) EP3113613A4 (enExample)
JP (1) JP6526066B2 (enExample)
KR (1) KR20160145558A (enExample)
CN (2) CN106455563A (enExample)
AU (2) AU2015227307A1 (enExample)
BR (1) BR112016020181A8 (enExample)
CA (1) CA2941518A1 (enExample)
IL (1) IL247529B (enExample)
MX (1) MX384877B (enExample)
RU (1) RU2735790C2 (enExample)
WO (1) WO2015134510A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352739B1 (en) * 2015-09-24 2021-10-27 Novartis AG Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
CN106967044B (zh) * 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN109394745A (zh) * 2017-08-17 2019-03-01 博瑞生物医药（苏州）股份有限公司 一种包含左旋肉碱和β-羟基丁酸化合物的组合物
JPWO2020213693A1 (enExample) * 2019-04-17 2020-10-22
WO2020227578A1 (en) * 2019-05-07 2020-11-12 Aciont Inc. Lipoic acid formulations
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CN113717770B (zh) * 2020-05-25 2022-06-03 中国石油天然气股份有限公司 一种金属加工油
GB202305212D0 (en) 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935962A (en) 1960-06-17 1963-09-04 Fujisawa Pharmaceutical Co Improvements in or relating to the production of 6.8-dithiooctanamides
US3855240A (en) 1969-04-28 1974-12-17 Exxon Research Engineering Co Sulfur containing heterocycles
US4210667A (en) 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
US4755528A (en) 1984-12-06 1988-07-05 Alcon Laboratories, Inc. High energy ionizing protective 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and N-acyl and N-alkyl derivatives thereof, compositions and method of use therefor
US6030950A (en) 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
WO1993002639A1 (en) 1991-08-06 1993-02-18 Autogenesis Technologies, Inc. Injectable collagen-based compositions for making intraocular lens
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1993025166A1 (en) 1992-06-10 1993-12-23 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
WO1994001096A1 (en) 1992-07-02 1994-01-20 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JPH08505119A (ja) 1992-07-06 1996-06-04 バイオミラ、インコーポレーテッド 接合目的のためのタンパク質の光活性化
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
US5465737A (en) 1992-07-15 1995-11-14 Schachar; Ronald A. Treatment of presbyopia and other eye disorders
BR9306848A (pt) 1992-08-07 1998-12-08 Keravision Inc Anel polimérico dividido para introdução no estroma
DE4345199C2 (de) * 1993-05-22 1995-10-12 Asta Medica Ag Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
US5395356A (en) 1993-06-04 1995-03-07 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
US5527774A (en) 1993-07-12 1996-06-18 Girard; Louis J. Dislocation of cataractous lens by enzymatic zonulolysis
US5665770A (en) 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
CA2185699A1 (en) 1994-04-04 1995-10-12 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US6063116A (en) 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5624955A (en) 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5686450A (en) 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
US6007510A (en) 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US5843184A (en) 1998-01-26 1998-12-01 Cionni; Robert J. Endocapsular tension ring and method of implanting same
US6153647A (en) 1998-11-12 2000-11-28 My-Tech, Inc. Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
US6472541B2 (en) 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
WO2000032235A1 (de) 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
US6288106B1 (en) 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6339102B1 (en) 1999-06-09 2002-01-15 The United States Of America As Represented By The Secretary Of The Army Method and composition for treating and preventing retinal damage
JP4476435B2 (ja) * 1999-07-22 2010-06-09 株式会社細川洋行 仕切部材、複室輸液容器および薬剤入り複室輸液容器の製造方法
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6387945B2 (en) 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
EP1303215A1 (en) 2000-07-10 2003-04-23 Koninklijke Philips Electronics N.V. Geometry matching for imaging medical apparatus
AU2001291677A1 (en) 2000-08-02 2002-02-13 Basf Aktiengesellschaft Method for producing lipoic acid and dihydrolipoic acid
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20050112113A1 (en) 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7914815B2 (en) 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US6923955B2 (en) 2000-08-16 2005-08-02 Newlens, Llc Presbyopia treatment by lens alteration
WO2002013863A2 (en) 2000-08-16 2002-02-21 Refocus, Llc. Presbyopia treatment by lens alteration
DE10045059A1 (de) 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US6703039B2 (en) 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
EP1808158A3 (en) 2001-01-19 2008-06-18 Newlens, LLC Presbyopia treatment by lens alteration
ATE446949T1 (de) 2001-03-19 2009-11-15 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
CA2448062A1 (en) 2001-05-25 2002-12-05 Ceremedix, Inc. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
FR2832637B1 (fr) 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
ITMI20011232A1 (it) 2001-06-12 2002-12-12 St Microelectronics Srl Metodo di riprogrammazione successiva ad una operazione di cancellazione di una matrice di celle di memoria non volatile, in particolare di
AU2002254546A1 (en) 2002-04-03 2003-10-20 Mitchell A. Avery Lipoic acid analogs useful as provitamins and antioxidants
US20050137124A1 (en) 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
AU2003264412A1 (en) 2002-09-13 2004-04-30 Oga Research, Incorporated Melanin extinguisher
WO2004028536A1 (en) * 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7941211B2 (en) 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US7585846B2 (en) 2003-11-25 2009-09-08 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
FR2869531B1 (fr) 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US7264279B2 (en) 2004-07-08 2007-09-04 Fab-Tech, Inc. Segmented conduit having a monolithic lining
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
US20060275278A1 (en) * 2005-06-02 2006-12-07 Choy Camus K M Method and ophthalmic formulation for eye protection or treatment
WO2007011874A2 (en) 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
US20070055070A1 (en) 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
US7973073B2 (en) 2006-06-16 2011-07-05 Indigene Pharmaceuticals, Inc. Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
WO2008067403A2 (en) 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
BRPI0720000A2 (pt) * 2006-12-08 2013-12-17 Sachtleben Chemie Gmbh Corpo moldado contendo titâno
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
GB2459809A (en) 2007-02-22 2009-11-11 Children S Hospital And Res Ct Fatty acid formulations and methods of use thereof
US8318795B2 (en) 2007-03-01 2012-11-27 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
UA86441C2 (ru) 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
CN101848715A (zh) * 2007-08-09 2010-09-29 千寿制药株式会社 含吡诺克辛的二液性滴眼剂
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
EP2442645B1 (en) 2009-06-15 2014-08-27 Encore Health, Llc Choline esters
DE102010009475B4 (de) * 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
MX353154B (es) * 2011-01-04 2017-12-20 Novaliq Gmbh Emulsiones de aceite/agua que comprenden alcanos semifluorados.
AU2013211645B2 (en) * 2012-01-23 2017-06-15 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP3078384A1 (en) * 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions

Also Published As

Publication number Publication date
IL247529A0 (en) 2016-11-30
KR20160145558A (ko) 2016-12-20
EP3113613A4 (en) 2019-03-13
MX2016011290A (es) 2017-04-27
MX384877B (es) 2025-03-14
AU2015227307A1 (en) 2016-10-13
BR112016020181A8 (pt) 2021-06-29
JP2017511816A (ja) 2017-04-27
US20200281891A1 (en) 2020-09-10
RU2016137784A (ru) 2018-04-03
CN106455563A (zh) 2017-02-22
RU2016137784A3 (enExample) 2018-10-18
EP3113613A1 (en) 2017-01-11
AU2019240641A1 (en) 2019-10-24
CN112641720A (zh) 2021-04-13
CA2941518A1 (en) 2015-09-11
WO2015134510A1 (en) 2015-09-11
AU2019240641B2 (en) 2020-10-29
RU2735790C2 (ru) 2020-11-09
BR112016020181A2 (pt) 2017-08-15
US11426381B2 (en) 2022-08-30
JP6526066B2 (ja) 2019-06-05
US20160354340A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
ZA201707981B (en) Compositions of obeticholic acid and methods of use
IL280485A (en) Sustained-release pridopidine preparations
IL247529B (en) Preparations of choline ester lipoic acid and methods of use
SG11201703997XA (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SG11201706089RA (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
SG10201607129TA (en) Tripentyl esters of trimellitic acid
SG11201610228RA (en) Methods and compositions of bile acids and salts for reduction of fat
IL258922A (en) Methods for the preparation of obeticholic acid and derivatives thereof
SG11201608217PA (en) Fatty acid composition and use thereof
EP3105327A4 (en) Compositions and methods of using microrna inhibitors
GB201410250D0 (en) Improvements to nasal compositions and method of use thereof
IL258258B (en) Lipoic acid choline ester preparations and methods for producing biocompatible ophthalmic formulations
EP3190886A4 (en) Compositions and methods of use thereof
EP3139741A4 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
PT3215132T (pt) Amantadina para melhorar a marcha em esclerose múltipla
IL257223A (en) New crystalline form and acetic acid adducts of palbociclib
EP2968246A4 (en) OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
GB2561121B (en) Branched acid emulsifier compositions and methods of use
HUE044559T2 (hu) Lerakódást gátló készítmények és alkalmazási eljárásaik
EP3227299A4 (en) Formulation inhibiting effects of low acid environment
PT3125867T (pt) Composição hiperosmolar de ácido hialurónico
IL248494A0 (en) Methods and compositions for the treatment of fat storage diseases
SG11201609485RA (en) Detection of acrylic acid
GB201408171D0 (en) Formulation and method of manufacture

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed